Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease
Yıl: 2021 Cilt: 27 Sayı: 3 Sayfa Aralığı: 140 - 144 Metin Dili: İngilizce DOI: 10.4274/tod.galenos.2021.45403 İndeks Tarihi: 30-06-2022
Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease
Öz: Objective: This study aimed to investigate the serum levels of calprotectin, hepcidin, iron, and ferritin in Behçet’s disease (BD).
Materials and Methods: This study included 40 patients with BD who met the diagnostic criteria of the BD International Study Group (1990)
and 40 healthy control participants. Serum high-sensitive C-reactive protein (hsCRP), hepcidin, calprotectin, ferritin, iron, and unsaturated
iron-binding capacity (UIBC) levels were determined in all study participants.
Results: Statistically significant difference was found between the groups in respect of calprotectin (p<0.05), UIBC (p<0.05), hsCRP (p<0.05),
and hemoglobin (p<0.05) levels. No statistically significant differences were determined between the patients and the controls in terms of
hepcidin, iron, and ferritin levels. Cut-off value of 212.3 pg/mL for calprotectin was determined to identify patients with BD having a sensitivity
and specificity of 100% and 90%, respectively.
Conclusion: Serum calprotectin may be a useful biomarker in the evaluation of inflammatory status and BD diagnosis. Total iron-binding
capacity and hemoglobin may be more useful in evaluating iron deficiency anemia in patients with BD.
Anahtar Kelime: Behçet Hastalığında Serum Kalprotektin ve Demir Metabolizması Biyobelirteç Düzeyleri
Öz: Amaç: Bu çalışmanın amacı Behçet hastalığında (BH) serum kalprotektin, hepsidin, demir ve ferritin düzeylerini araştırmaktır.
Gereç ve Yöntem: Çalışmaya Uluslararası BH Çalışma Grubu tanı kriterlerine (1990) göre 40 Behçet hastası ve 40 sağlıklı birey dahil edildi.
Çalışmaya katılan tüm bireylerin serum yüksek duyarlı C-reaktif protein (hsCRP), hepsidin, kalprotektin, ferritin, demir ve doymamış demir
bağlama kapasitesi (UIBC) seviyeleri belirlendi.
Bulgular: Gruplar arasında serum kalprotektin (p<0,05), UIBC (p<0,05), hsCRP (p<0,05) ve hemoglobin (p<0,05) düzeyleri açısından
istatistiksel olarak anlamlı fark bulundu. Hastalar ve kontroller arasında serum hepsidin, demir ve ferritin düzeyleri açısından istatistiksel olarak
anlamlı fark saptanmadı. Kalprotektin kesme değeri 212,3 (pg/mL) bulundu ve bu değer BH için duyarlılık %100 ve özgüllük %90 idi.
Sonuç: Serum kalprotektin, enflamatuvar durumun değerlendirilmesinde ve BH’nin tanısında faydalı biyobelirteç olabilir. Toplam demir
bağlama kapasitesi ve hemoglobin, Behçet hastalarında demir eksikliği anemisini değerlendirmek için daha faydalı olabilir
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Karadağ A, Karadağ M, Bora A, Hayta E, Çetin AB, Doğan SC, et al. Evaluation of hearing loss and tinnitus in Behcet’s disease. Eur Arch Otorhinolaryngol 2019;276:2691-6.
- 2. Arica DA, Akşan B, Örem A, Altinkaynak BA, Yayli S, Sönmez M. High levels of endothelial progenitor cells and circulating endothelial cells in patients with Behçet’s disease and their relationship to disease activity. An Bras Dermatol 2019;94:320-6.
- 3. Rustemoglu A, Erkol Inal E, Inanir A, Ekinci D, Gul U, Yigit S, et al. Clinical significance of NCOA5 gene rs2903908 polymorphism in Behçet’s disease. EXCLI J 2017;16:609-17.
- 4. Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M, Jiménez Hernández C, Riebeling-Navarro C, Nava Zavala A, et al. Etiopathogenesis of Behcet’s disease. Autoimmun Rev 2010;9:241- 5.
- 5. Perazzio SF, Soeiro-Pereira PV, Dos Santos VC, de Brito MV, Salu B, Oliva MLV, et al. Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet’s disease. Arthritis Res Ther 2017;19:235.
- 6. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 2012;11:687-98.
- 7. Romand X, Bernardy C, Nguyen MVC, Courtier A, Trocme C, Clapasson M, et al. Systemic calprotectin and chronic inflammatory rheumatic diseases. Joint Bone Spine 2019;86:691-8.
- 8. Nakashige TG, Zhang B, Krebs C, Nolan EM. Human calprotectin is an iron-sequestering host-defense protein. Nat Chem Biol 2015;11:765-71.
- 9. Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther 2016;18:160.
- 10. Reveille JD. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin Rheumatol 2015;34:1009-18.
- 11. Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci 2014;19:164-74.
- 12. Silva B, Faustino P. An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim Biophys Acta 2015;1852:1347-59.
- 13. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6.
- 14. Mohammed MF, Belal D, Bakry S, Marie MA, Rashed L, Eldin RE, et al. A study of hepcidin and monocyte chemoattractant protein-1 in Egyptian females with systemic lupus erythematosus. J Clin Lab Anal 2014;28:306-9.
- 15. Østgård RD, Glerup H, Jurik AG, Kragstrup TW, Stengaard-Pedersen K, Hetland ML, et al. Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients. Scand J Rheumatol 2017;46:441-5.
- 16. Ganz T. Hepcidin--a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005;18:171-82.
- 17. Özşeker B, Şahin C, Özşeker HS, Efe SC, Kav T, Bayraktar Y. The Role of Fecal Calprotectin in Evaluating Intestinal Involvement of Behçet’s Disease. Dis Markers 2016;2016:5423043.
- 18. Kim DH, Park Y, Kim B, Kim SW, Park SJ, Hong SP, et al. Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behçet’s disease. J Gastroenterol Hepatol 2017;32:595-601.
- 19. Baillet A, Trocmé C, Romand X, Nguyen CMV, Courtier A, Toussaint B, et al. Calprotectin discriminates septic arthritis from pseudogout and rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1644- 18.
- 20. Omma A, Sandikci SC, Colak S, Tecer D, Yucel C, Ozbalkan Z. Serum calprotectin and ischemia modified albumin levels as markers of disease activity in Behçet’s disease. Postepy Dermatol Alergol 2018;35:609-613.
- 21. Oktayoglu P, Mete N, Caglayan M, Bozkurt M, Bozan T, Em S, et al. Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behçet’s disease and its association with disease activity and quality of life. Scand J Clin Lab Invest 2015;75:106-12.
- 22. Viemann D, Barczyk K, Vogl T, Fischer U, Sunderkötter C, SchulzeOsthoff K, et al. MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program. Blood 2007;109:2453-60.
- 23. Hirono K, Foell D, Xing Y, Miyagawa-Tomita S, Ye F, Ahlmann M, et al. Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease. J Am Coll Cardiol 2006;48:1257-64.
- 24. Huang J, Yin Z, Song G, Cui S, Jiang J, Zhang L. Discriminating Value of Calprotectin in Disease Activity and Progression of Nonradiographic Axial Spondyloarthritis and Ankylosing Spondylitis. Dis Markers 2017;2017:7574147.
- 25. Weiss G, Schett G. Anaemia in inflammatory rheumatic diseases. Nat Rev Rheumatol 2013;9:205-15.
- 26. Jankowska EA, Tkaczyszyn M, Drozd M, Ponikowski P. Monitoring of iron status in patients with heart failure. Eur Heart J Suppl 2019;21(Suppl M):M32-M5.
- 27. Kunireddy N, Jacob R, Khan SA, Yadagiri B, Sai Baba KSS, Rajendra Vara Prasad I, et al. Hepcidin and Ferritin: Important Mediators in Inflammation Associated Anemia in Systemic Lupus Erythematosus Patients. Indian J Clin Biochem 2018;33:406-13.
- 28. Swellam M, Gabal KM, Youssef SS. Interleukin-1 receptor antagonist gene polymorphism and hepcidin in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity. IUBMB Life 2013;65:883-8.
- 29. Odabas AR, Karakuzu A, Cetinkaya R, Selcuk Y, Keles S, Bilen H. Increased serum ferritin levels in active Behçet’s disease. Int J Clin Pract 2002;56:310-1.
- 30. Gonul M, Gul U, Cakmak SK, Soylu S, Kilic A. Serum iron and ferritin levels in Behçet’s disease. Indian J Dermatol Venereol Leprol 2010;76:85.
- 31. Kuo YS, Chang JY, Wang YP, Wu YC, Wu YH, Sun A. Significantly higher frequencies of hemoglobin, iron, vitamin B12, and folic acid deficiencies and of hyperhomocysteinemia in patients with Behcet’s disease. J Formos Med Assoc 2018;117:932-8.
- 32. Koca SS, Isik A, Ustundag B, Metin K, Aksoy K. Serum pro-hepcidin levels in rheumatoid arthritis and systemic lupus erythematosus. Inflammation 2008;31:146-53.
- 33. Demir B, Cicek D, Aydin S, Doğan Başkaya F. Erden I. Ucak H, et al. Relationship between metabolic syndrome and serum hepcidin level in patients with behcet’s disease. Glob. Dermatology 2015;2:99-102.
- 34. Cicek D, Dağlı AF, Aydin S, Baskaya Dogan F, Dertlioğlu SB, Uçak H, et al. Does hepcidin play a role in the pathogenesis of aphthae in Behçet’s disease and recurrent aphthous stomatitis? J Eur Acad Dermatol Venereol 2014;28:1500-6.
- 35. Killip S, Bennett JM, Chambers MD. Iron deficiency anemia. Am Fam Physician 2007;75:671-8.
| APA | KARADAĞ A, DOĞAN H (2021). Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease. , 140 - 144. 10.4274/tod.galenos.2021.45403 |
| Chicago | KARADAĞ Ahmet,DOĞAN Halef Okan Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease. (2021): 140 - 144. 10.4274/tod.galenos.2021.45403 |
| MLA | KARADAĞ Ahmet,DOĞAN Halef Okan Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease. , 2021, ss.140 - 144. 10.4274/tod.galenos.2021.45403 |
| AMA | KARADAĞ A,DOĞAN H Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease. . 2021; 140 - 144. 10.4274/tod.galenos.2021.45403 |
| Vancouver | KARADAĞ A,DOĞAN H Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease. . 2021; 140 - 144. 10.4274/tod.galenos.2021.45403 |
| IEEE | KARADAĞ A,DOĞAN H "Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease." , ss.140 - 144, 2021. 10.4274/tod.galenos.2021.45403 |
| ISNAD | KARADAĞ, Ahmet - DOĞAN, Halef Okan. "Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease". (2021), 140-144. https://doi.org/10.4274/tod.galenos.2021.45403 |
| APA | KARADAĞ A, DOĞAN H (2021). Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease. Türk Osteoporoz Dergisi, 27(3), 140 - 144. 10.4274/tod.galenos.2021.45403 |
| Chicago | KARADAĞ Ahmet,DOĞAN Halef Okan Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease. Türk Osteoporoz Dergisi 27, no.3 (2021): 140 - 144. 10.4274/tod.galenos.2021.45403 |
| MLA | KARADAĞ Ahmet,DOĞAN Halef Okan Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease. Türk Osteoporoz Dergisi, vol.27, no.3, 2021, ss.140 - 144. 10.4274/tod.galenos.2021.45403 |
| AMA | KARADAĞ A,DOĞAN H Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease. Türk Osteoporoz Dergisi. 2021; 27(3): 140 - 144. 10.4274/tod.galenos.2021.45403 |
| Vancouver | KARADAĞ A,DOĞAN H Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease. Türk Osteoporoz Dergisi. 2021; 27(3): 140 - 144. 10.4274/tod.galenos.2021.45403 |
| IEEE | KARADAĞ A,DOĞAN H "Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease." Türk Osteoporoz Dergisi, 27, ss.140 - 144, 2021. 10.4274/tod.galenos.2021.45403 |
| ISNAD | KARADAĞ, Ahmet - DOĞAN, Halef Okan. "Serum Calprotectin and Iron Metabolism Biomarker Levels in Behçet’s Disease". Türk Osteoporoz Dergisi 27/3 (2021), 140-144. https://doi.org/10.4274/tod.galenos.2021.45403 |
